Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

zzlangerhans (99.75) Submitted: 7/19/2012 2:09:35 AM : Start Price: $3.13 LXRX Score: +19.21

In late June Lexicon announced positive results from the phase IIb trial of glucose transporter inhibitor LX4211. I don't really have a complaint about the data. It looks good. But the study doesn't clearly establish where LX4211 might fit into diabetes management, a rapidly evolving field with numerous proprietary and generic therapies available. I think when Lexicon has a positive catalyst, investors sometimes forget about their enormous 480M share count and concurrent bloated market cap. When the share price hit 3.2, the market cap approached 1.5B. That's quite a chunk of change for LX4211 and some other less inspiring pipeline candidates, and a hard level of interest to maintain in the years ahead before LX4211 can be commercialized.